In this retrospective observational clinical study, 167 children, aged 3 to 7 years, of both sexes, with a clinical history of recurrent respiratory infections, administered with bacterial extracts of first and second generation or Sinerga a nutritional product containing palmitoylethanolamide, bovine colostrum, phenylethylamine and the new generation of probiotic k1uyveromyces FM B0399, were observed. The goal of the study was to compare the supplementation with Sinerga with the supplementation with bacterial extracts, for the effect on the frequency of episodes of respiratory infection that had resulted in a prescription for antibiotics. The study focused retrospectively on the months from March 2013 to November 2012. The results showed a greater reduction in the frequency of respiratory infections with antibiotic therapy in the group of children supplemented with Sinerga than in the group treated with bacterial extracts. In particular, it was observed that 49.3% of the children supplemented with Sinerga, against 5% ofthose supplemented with extracts, had no infectious episodes requiring the administration of an antibiotic. 100% of subjects supplemented with Sinerga have had no more than two episodes of respiratory infection, while this condition, in the cohort treated with bacterial extracts, was observed in only 51 % of cases.
Respiratory tract infections in pediatric age are one of the most common reasons for medical visits and hospitalizations; they are associated with significant morbidity and mortality and represent the most common diseases in children and adolescents. Over time, the role of doctors has expanded in treating these diseases and adopting measures for the preservation of health and prophylaxis (1).
Upper airway respiratory infections in some children develop the syndrome of Recurrent Respiratory Infections (IRR) (2) , consisting in one of the following conditions:
•~6 respiratory infections per year, •~1 upper airway respiratory infection per month, from September to April,
•~3 lower airways respiratory infections per year.
According to epidemiological studies, it has been estimated that about 6% of children under 6 years of age has IRR. In developed countries, up to 25% of children under the age of 1 year, and 18% of children aged 1-4 years have IRR (l). The primary etiological agents ofIRR are viruses of different strains (3) . The bacterial superinfection is found in 60% of patients with symptoms of infection of the upper respiratory tract lasting at least 10 days (4). Children with IRR usually do not show complex syndromes, and the respiratory infections are the result of an important exposure to infectious agents during the first years oflife (5) .
In clinical practice, most children suffer from IRR of the upper airways, but, in about 10-30%, the lower airways are affected. It has been possible to identify in the population two peaks of incidence for IRR (6, 7): 6 to 12 months of age, after the passive assumption of the maternal immunoglobulins, when the synthesis of self-antibodies is retarded, and the time of entrance into community-life. The episodes of respiratory infection have the same course for symptoms, severity and duration in children who experience IRR, as in children with normal incidence of this type of infections. The frequency of acute episodes in children with IRR has the typical seasonality, with the highest incidence during autumn and winter (5) . Most children with IRR have no immune deficiencies, and IRR are not associated with infections ofother organ systems; it is obviously important to investigate in order to recognize the child with an underlying primary immunodeficiency, to treat him appropriately (8) . The pediatrician should try to discriminate between normal children with a high frequency of respiratory infections due to increased exposure to environmental risk factors, and children suffering from other medical conditions (immunological or not) which predispose to infectious respiratory diseases (6, 9) .
The occurrence of IRR often leads to the prescription of antibiotics, but if the etiology of the disease is viral this prescription is not needed and is likely to favor the development of bacterial resistance, in addition to being an unnecessary cost for the healthcare system.
In this study, we retrospectively examine two cohorts of pediatric patients with IRR, comparing the prophylactic effects of two different treatments, the first with bacterial extracts of first and second generation, acting through the stimulation of the immune system, and the second with the Sinerga, acting through the down -regulation of the mast cells and the direct and indirect contribution of various immune and growth factors. More specifically, Sinerga is reported to explicate a multifactorial activity through its components: palmitoylethanolamide determines an increase in the threshold for the degranulation of the mastcells, phenylalanine supports the maintenance of the normal concentration of dopamine in the body liquids, colostrum fosters an increased synthesis of immunoglobulins, Kluyveromyces B0399 normalizes the MALT (Mucosa Associated Lymphoid Tissue), stimulates IgA production and increases phagocitosis.
MATERIALS AND METHODS
This is a parallel, retrospective observational clinical study, for comparison of two cohorts of pediatric subjects with a clinical history of recurrent respiratory infections, distinguished by having being treated with Sinerga for 4 consecutive months, or with bacterial extracts for 3 consecutive months. Table I shows the criteria for inclusion and exclusion of subjects observed.
The aim of the study was to compare the two treatment groups (Sinerga and bacterial extracts) for the frequency of episodes of respiratory infection that had led to the prescription and intake of antibiotics.
The dosage prescribed for Sinerga is: month I, one sachet/day for 20 consecutive days, months 2, 3, 4, one sachet/day for 10 consecutive days as per recommended and approved instructions for use. The dosage prescribed for the bacterial extracts is that indicated in the leaflets of the products on the market.
The data collection was carried out by specialists in pediatrics. All records of diagnosis of acute respiratory infection which had a documented prescription of antibiotics were counted. For the purpose of the study, an antibiotic prescription was accounted as valid when it followed a condition in which the patient had shown fever over 38°C for at least 3 days. A descriptive statistical analysis of data for cohorts was carried out.
RESULTS
For a time interval of five months, from March 2013 to November 2012 included, data of67 patients treated with Sinerga were retrospectively collected, and on 100 patients treated with bacterial extracts of first and second generation. The time interval was chosen as representative of a typical period of intensification ofrespiratory disease in Italy. Table II shows the age variable in the two cohorts. extract treatments detected in the related group of patients. All the products are classified as bacterial vaccine. Table IV shows the distribution ofthe frequency of the episodes of respiratory infections with antibiotic treatment per subject, detected in the period March 2013 -November 2012 in the two cohorts. Fig. I shows the comparison of the two cohorts of treatment for the frequency of the episodes of respiratory infection with antibiotic treatment. The comparison between the results of the observations made on the two cohorts during the relative period indicate a higher protective capacity of Sinerga: 33 out of 67 subjects did not have any respiratory infection, compared with 5 out of 100 in the group treated with bacterial extracts.
By analyzing the frequency distribution we observe that 100% of subjects treated with Sinerga remained within the limit of 2 episodes ofrespiratory infection in 5 months, compared with 51% ofsubjects treated with bacterial extracts. No effects attributed by the pediatrician to Sinerga or bacterial extracts were detected.
DISCUSSION
Pediatric recurrent respiratory infections (lRR) represent a clinical and pharmacoeconomic problem. In fact, they cause the repeated use in children of antibiotic treatments that are a factor inductive of bacterial resistances and of overspending of patients' and National Health Service money.
In this study, retrospectively over a period of five months, two cohorts of subjects between the ages of 3 and 7 years with a history of IRR, treated for the prevention of episodes of respiratory infection with bacterial extracts of first and second generation or with Sinerga, were compared. A greater prophylactic potency ofSinerga was observed compared to bacterial extracts, with 49.5% of subjects free from infections during the observation period offive months, compared with 5% of those treated with bacterial extracts. In addition, 100% of subjects supplemented with Sinerga had not had more than two episodes of respiratory infection requiring antibiotic administration, whereas, in the group treated with bacterial extracts, this condition was observed in only 51% of cases. If we assume for sufficiently demonstrated that the bacterial extracts have shown protective effects in children with IRR (10-15), this study demonstrates that Sinerga can have a greater efficacy.
